Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Aktiva vinster i hjärnan med hjälp av träning under åldrande (AGUEDA)

20 september 2026 uppdaterad av: Irene Esteban-Cornejo, Universidad de Granada

Aktiva vinster i hjärnan med hjälp av träning under åldrande: AGUEDA-försök

AGUEDA (Active Gains in brain using Exercise During Aging) is a randomized controlled trial designed to examine the effects of a 24-week resistance exercise program on brain health in cognitively normal adults between 65-80 years of age.

Studieöversikt

Status

Avslutad

Detaljerad beskrivning

Exercise has emerged as the most promising non-pharmacologic intervention for improving brain health in older adults. The main aim of AGUEDA (Active Gains in brain using Exercise During Aging) trial is to examine the effects of a 6-month resistance exercise program on executive function in cognitively normal older adults. The secondary aims are (i) to examine the effects of exercise on central and peripheral brain markers, and (ii) to investigate mediators and moderators of the exercise-derived improvements observed in executive function and brain markers. AGUEDA is a randomized controlled trial in which 90 cognitively normal older adults, aged 65-80 years old, will be randomized into an exercise group (n=45) or a wait-list control group (n=45). Participants assigned to the exercise group will participate in a 24-week resistance exercise program (3 sessions/week, 60 min/session), while the control group will be asked to maintain their usual lifestyle. A comprehensive neuropsychological test battery, amyloid PET scan, cutting-edge MRI scan, DXA scan, physical fitness, physical function and physical activity measures will be used. Blood, saliva and fecal samples will be collected. Mental health and psychosocial variables will be self-reported.

Studietyp

Interventionell

Inskrivning (Faktisk)

90

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Andalusia
      • Granada, Andalusia, Spanien, 18016
        • University of Granada

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

65 år till 80 år (Äldre vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Men and women 65 - 80 years.
  • Able to speak and read fluent Spanish.
  • Living in community during the study.
  • Reliable means of transportation.
  • Being physical inactive (i.e., not to be participating in the last 6 months in any resistance exercise program, or accumulating less than 600 METS/Week of moderate-vigorous physical activity).
  • Classified as cognitively normal according to Stics-m MMSE and MOCA tests.

Exclusion Criteria:

  • Ambulatory with pain or regular use of an assisted walking device.
  • Medical contraindication for inclusion in an exercise program.
  • Neurological condition (Multiple Sclerosis, Parkinson Disease, Dementia) or brain injury (traumatic or stroke).
  • Current diagnosis and treatment of a DSM-V Axis I or II disorder including major depression and seeing a psychologist, therapist, or psychiatrist.
  • History of major psychiatric illness including schizophrenia, general anxiety disorder or depression (GDS-30>=15).
  • Current treatment for congestive heart failure, angina, uncontrolled arrhythmia, deep venous thrombosis or other cardiovascular event.
  • Myocardial infarction, coronary artery bypass grafting, angioplasty or other cardiac condition in the past year.
  • Current or previous treatment for any type of cancer.
  • Type I Diabetes or uncontrolled Type II Diabetes defined as Insulin dependent or Hba1C greater than 10.
  • Recent treatment for alcohol or substance abuse.
  • Presence of metal implants (e.g., pacemaker, stents, joint replacement) that would be MRI ineligible.
  • Claustrophobia.
  • Color blindness.
  • Diagnosis of COVID-19 with hospitalization in intensive care unit.
  • Any other consideration that interferes with the study aims and could be a risk to the participant, at the discretion of the researcher.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Förebyggande
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: 24-week resistance exercise program

Participants will engage in supervised 24-week resistance exercise program with goal of maintaining 180 minutes of exercise per week.

This group will perform a 24-week resistance exercise program. Participants will engage in 180 minutes/week of resistance exercise (3 supervised sessions peer week, 60 min/session). The training will consist of a combination of upper and lower body exercises using elastic bands and participants' body weight as the primary resistance. Exercise load and intensity will be based on the number of repetitions (i.e.,10-12 repetitions), resistance of the elastic bands, in ascending order with seven intensities, and also on the exercises' difficulty (i.e., three levels). The prescribed targeted intensity will reach 70-80% of the participants' maximum rating perceived exertion (i.e., 7-8 RPE).The progression (horizontal) will be standardized according to the execution time and RPE, and individualized according to execution speed and band resistance. Heart rate will be monitored in all sessions. Further, intrinsic motivation before and after session and sleep quality will be registered.

Inget ingripande: Wait-list control group

Control group will be asked to maintain their usual lifestyle.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in executive function
Tidsram: Baseline, 3 months and 6 months

The main outcome is change in executive function from baseline to 6 months. The 3-month measure is used to assess the trajectory of the change. A comprehensive neuropsychological battery will assess several domains of executive function: working memory, cognitive flexibility and inhibitory control.

Baseline, 3 months and 6 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in brain amyloid beta
Tidsram: Baseline and 6 months

PET (positron emission tomography) scan using the tracer Neuraceq (Florbetaben F18) will measure levels of the protein amyloid beta in the brain.

Baseline and 6 months
Change in brain morphology
Tidsram: Baseline and 6 months

MRI (magnetic resonance imaging) will measure brain morphology including volume, area, cortical thickness and shapes by a T1-weighted MPRAGE structural sequence.

Baseline and 6 months
Change in hippocampal brain morphology
Tidsram: Baseline and 6 months

MRI (magnetic resonance imaging) will measure hippocampal morphology including volume, area, cortical thickness, shapes by a high resolution hippocampus sequence.

Baseline and 6 months
Change in white matter structure
Tidsram: Baseline and 6 months

MRI (magnetic resonance imaging) will measure white matter structure and lesions by diffusion weighted acquisition sequence.

Baseline and 6 months
Change in brain function
Tidsram: Baseline and 6 months

MRI (magnetic resonance imaging) will measure brain function including both resting state and n-back working memory task-evoked patterns. Measures of brain activity and brain connectivity will be calculated.

Baseline and 6 months
Change in cerebral blood flow
Tidsram: Baseline and 6 months

MRI (magnetic resonance imaging) will measure cerebral blood flow by Pseudo-Continuous Arterial Spin Labeling (pCASL) sequence.

Baseline and 6 months
Change in peripheral amyloid beta
Tidsram: Baseline and 6 months

Saliva and blood samples will be used to determine peripheral amyloid beta

Baseline and 6 months
Change in other peripheral neurology biomarkers
Tidsram: Baseline and 6 months

Saliva and blood samples will be used to determine peripheral neurology biomarkers including brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF) and cathepsin B (CTSB).

Baseline and 6 months
Change in memory performance
Tidsram: Baseline and 6 months

Visuospatial memory will be assessed by the Rey-Osterreith figure (ROF) test, verbal memory by the Rey Auditory Verbal Learning Test (RAVLT) and confrontational word memory by the boston Naming Test (short version, BNT).

Baseline and 6 months
Change in fluid and crystallized intelligence
Tidsram: Baseline and 6 months

Intelligence will be assessed by the Wechsler Adult Intelligence Scale (WAIS-IV). 3 subtests for crystallized intelligence (Similarities, Vocabulary, information) and 3 subtests for fluid intelligence (Block Design, Matrix Reasoning, Visual Puzzles).

Baseline and 6 months
Change in general cognition
Tidsram: Baseline and 6 months

General cognition will be assessed by the Telephone Interview for Cognitive Status (STICS-m), the Mini mental state examination (MMSE) and the Montreal Cognitive Assessment (MOCA. vocabulary/language and subjective and objective cognitive decline will be assessed by paper-based tests.

Baseline and 6 months
Change in other cognitive outcomes
Tidsram: Baseline and 6 months

Vocabulary/language, and subjective and objective cognitive decline will be assessed by paper-based tests.

Baseline and 6 months

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Changes in muscular strength
Tidsram: Baseline, 3 months (only for field-based tests) and 6 months

Muscular strength will be assessed by laboratory (i.e. isokinetic test) and field- based (i.e., handgrip and functional tests) tests

Baseline, 3 months (only for field-based tests) and 6 months
Change in physical function
Tidsram: Baseline, 3 months and 6 months

Senior Fitness Test and Short Physical Performance Battery will assess overall physical functioning and z-scores will be calculated.

Baseline, 3 months and 6 months
Change in gait speed and variability
Tidsram: Baseline and 6 months

Gait analysis will be assessed by the OptoGait System

Baseline and 6 months
Change in cardiorespiratory fitness
Tidsram: Baseline and 6 months

Cardiorespiratory fitness will be assessed by 2 field-based tests ( i.e., 6-min walking test and 2-km walking test)

Baseline and 6 months
Change in mental health outcomes, specifically psychological ill-being
Tidsram: Baseline and 6 months

A battery of questionnaire will assess psychological ill-being (i.e. depression, anxiety, stress or negative affect).

Baseline and 6 months
Change in mental health outcomes, specifically psychological well-being.
Tidsram: Baseline and 6 months

A battery of questionnaire will assess psychological well-being (i.e. self-esteem, self-concept, self-efficacy, self-image, positive affect, optimism, happiness and satisfaction with life).

Baseline and 6 months
Change in quality of life
Tidsram: Baseline and 6 months

This will be self-reported using the Health Survey Short Form (SF-36).

Baseline and 6 months
Change in 24-hours movement behaviors
Tidsram: Baseline and 3 months

Physical activity at different intensities (average min/day), sedentary time (average min/day) and sleep (average min/day) will be measured using Actigraph GT3X + accelerometers

Baseline and 3 months
Change in sedentary behaviors
Tidsram: Baseline and 6 months

Type of sedentary behaviors will be self-reported by questionnaire.

Baseline and 6 months
Change in diet behaviors
Tidsram: Baseline and 6 months

This will be self-reported using the food-frequency questionnaire (FFQ) and the PREDIMED-14 questionnaire.

Baseline and 6 months
Change in body composition
Tidsram: Baseline and 6 months

Body composition [i.e., lean mass (kg), fat mass (kg), and bone mineral content and density (z-score)] will be assessed using a dual-energy x-ray absorptiometer (DXA). Full- body, bilateral hips and lumbar spine scans will be acquired.

Baseline and 6 months
Change in neck adipose tissue
Tidsram: Baseline and 6 months

Neck adipose tissue will be assessed by MRI

Baseline and 6 months
Change in blood pressure
Tidsram: Baseline and 6 months

Systolic and diastolic blood pressure will be assessed by a blood pressure monitor

Baseline and 6 months
Change in peripheral inflammatory and cardiovascular biomarkers
Tidsram: Baseline and 6 months

Saliva and blood samples will be used to determine peripheral biomarkers including tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1beta), glucose, insulin, HDL and LDL cholesterol

Baseline and 6 months
Change in epigenetics and gene expression
Tidsram: Baseline and 6 months

Blood samples will be stored for genetic analyses, including APOE and BDNF genotypes

Baseline and 6 months
Change in oral and gut microbiota
Tidsram: Baseline and 6 months

Saliva and fecal samples will be used to determine oral and gut microbiota including the most representative phyla (i.e., firmicutes, bacteroidetes, and proteobacteria.

Baseline and 6 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Användbara länkar

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

2 januari 2021

Primärt slutförande (Faktisk)

11 december 2022

Avslutad studie (Faktisk)

11 december 2022

Studieregistreringsdatum

Först inskickad

17 oktober 2021

Först inskickad som uppfyllde QC-kriterierna

22 december 2021

Första postat (Faktisk)

11 januari 2022

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

24 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

20 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera